Edition:
United Kingdom

Livzon Pharmaceutical Group Inc (1513.HK)

1513.HK on Hong Kong Stock

56.70HKD
20 Apr 2018
Change (% chg)

HK$-2.00 (-3.41%)
Prev Close
HK$58.70
Open
HK$58.60
Day's High
HK$59.60
Day's Low
HK$56.00
Volume
1,919,200
Avg. Vol
784,474
52-wk High
HK$71.60
52-wk Low
HK$35.88

Select another date:

Thu, Feb 8 2018

CORRECTED-BRIEF-Livzon Pharmaceutical Unit's JV Livzon Biologics' Capital Will Be Boosted By 600 Mln Yuan (Feb 7)

* SAYS CAPITAL AT UNIT'S JV LIVZON BIOLOGICS WILL BE BOOSTED BY 600 MILLION YUAN ($94.94 million) Source text in Chinese: http://bit.ly/2nMWH27 Further company coverage: ($1 = 6.3201 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Livzon Pharmaceutical Group Announces Proposed Cash Dividend Distribution & Share Issue

* ‍RECEIVED NOTICE FROM SHAREHOLDER PROPOSING ISSUE OF 3 BONUS SHARES FOR EVERY 10 SHARES TO ALL SHAREHOLDERS

BRIEF-Livzon Pharmaceutical Group Says Joincare To Sell 49 PCT Equity Interests In Livzon Mab

* PROPOSES TO ENTER AGREEMENT PURSUANT TO WHICH JOINCARE TO SELL 49% EQUITY INTERESTS IN LIVZON MAB FOR RMB294 MILLION Source text for Eikon: Further company coverage:

REFILE-BRIEF-Livzon Pharmaceutical'ss Board Agrees Unit To Invest $30 Mln In Global Health Science Fund II

* SAYS BOARD AGREES UNIT TO INVEST $30 MILLION IN GLOBAL HEALTH SCIENCE FUND II, L.P. Source text in Chinese: http://bit.ly/2CVb0qK Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Livzon Pharmaceutical Group receives subsidy of 12.8 mln yuan

* Says it received subsidy of 12.8 million yuan for injection internationalization and development related projects

BRIEF-Livzon Pharmaceutical Group unit receives approval for drug clinical trial

* Says Zhuhai-based biotechnology unit received drug clinical trial approval for drug named Recombinant Human anti-RANKL Monoclonal Antibody Solution for Injection

BRIEF-Livzon Pharmaceutical Co Announces Change In Shareholding Structure Of Livzon MABPharm

* CO & JOINCARE PHARMACEUTICAL INDUSTRY ENTERED FRAMEWORK AGREEMENT RELATING TO CAPITAL CONTRIBUTION TO LIVZON BIOLOGICS

BRIEF-Livzon Pharmaceutical Group unit receives approval for drug clinical trial

* Says its unit received drug clinical trial approval for Recombinant Humanized anti-PD-1 Monoclonal Antibody for Injection

BRIEF-Livzon Pharmaceutical's net profits up in Q3, Jan-Sept

* Says Q3 net profit up 1,719.2 percent y/y at 3.7 billion yuan ($556.85 million), 9-month net profit up 590.7 percent y/y at 4.2 billion yuan

BRIEF-Livzon Pharmaceutical sees FY net profit attributable between RMB4.32 bln - RMB4.48 bln

* Sees FY net profit attributable between RMB4.32 billion - RMB4.48 billion Source text for Eikon: Further company coverage:

Select another date: